AstraZeneca refines cancer focus, shares tracked against big pharma peers
22.06.2026 - 15:49:54 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-22, 15:48.
AstraZeneca (US6549022043) continues to sharpen its oncology profile after the recent US approval of Truqap in prostate cancer, a move closely watched on the NYSE where the shares trade via AZN.
What Reuters and RNS highlight
On 15 June 2026 AstraZeneca announced that Truqap (capivasertib), in combination with standard hormone therapy, received US approval for certain metastatic prostate cancer patients, according to an RNS release noted by Investegate.
The approval strengthens AstraZeneca's already sizeable oncology franchise, which includes targeted therapies such as Tagrisso and Imfinzi, and adds another late-stage cancer asset in the US market where Pfizer and Novartis are major peers.
Position among big pharma peers
With a London primary listing and inclusion in the FTSE 100, AstraZeneca is often compared with peers like GSK in the UK and global rivals Pfizer and Novartis; MarketScreener lists the group’s market value at more than 200 billion pounds on the LSE quote page for AZN.
Jefferies reiterated a Buy recommendation on AstraZeneca on 16 June 2026, according to a broker note summary on MarketScreener’s AstraZeneca page, underlining the supportive stance from at least one major research house.
All news and analysis on the AstraZeneca shares
Further company announcements, analyst commentary and price data on AstraZeneca can be found in the dedicated topic overview.
The products behind AstraZeneca
AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal, metabolism and respiratory diseases; Tagrisso for lung cancer, Farxiga for diabetes and heart failure, and Imfinzi for various cancers are among its key global products.
Where the AstraZeneca shares trade today
The AstraZeneca shares (US6549022043) most actively trade in London under ticker AZN, while the US-listed AZN American depositary shares recently changed hands around 175 US dollars on the NYSE in indicative pricing.
Key data on the AstraZeneca shares
- Company: AstraZeneca PLC
- ISIN: US6549022043
- WKN: 886455
- Ticker: AZN
- Trading venue: NYSE (ADR) / London Stock Exchange
- Price (as of 2026-06-22, 15:30): 175.00 USD (ADR, indicative)
- Market cap: approximately 205 billion GBP (London listing, June 2026)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.
